Company

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink
Finanical ReportsHengrui Pharmaceuticals

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) released its financial report for the third quarter of 2026, posting operating revenue of RMB 8.953 billion, up 20.55% year-on-year, and…

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Fosun Pharma Posts 9M 2026 Results – Revenue Rises 5.81% to RMB 30.5 Billion as Innovative Drug Growth Fuels Profits and R&D Spending Surges 31%

Fosun Pharma Posts 9M 2026 Results – Revenue Rises 5.81% to RMB 30.5 Billion as Innovative Drug Growth Fuels Profits and R&D Spending Surges 31%

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs
Auto-immuneClinical trial approval / initiation

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China
GeneScience Pharmaceutical

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
ADC / XDCCancer

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo
Auto-immuneClinical trial approval / initiation

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo

Show More